The detection of specific antibodies, such as Anti-Phenolic Glycolipid-1 (PGL-1) immunoglobulin M (IgM), has been used as a biomarker to identify individuals at a higher risk of developing clinical leprosy (Pierneef et al., 2024). This evidence concerns the gene SDHD and leprosy.